Enlie Pharmaceutical JSC

Enlie Pharmaceutical JSC EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enlie Pharmaceutical JSC (BCP.VN) as of Oct 29, 2026 is 4.23 B VND. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.23 B VND — a change of -231.10% (higher).

EBITDA

4.23 BVND

YoY

-231.10%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enlie Pharmaceutical JSC is 2024 4.23 B VND. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enlie Pharmaceutical JSC was 2023 -3.23 B VND. It decreases by -231.10% higher compared to the previous year.

The Enlie Pharmaceutical JSC EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2017
8.80 B VND
Jan 1, 2018
14.65 B VND
Jan 1, 2019
-3.01 B VND
Jan 1, 2020
-11.74 B VND
Jan 1, 2021
-4.19 B VND
Jan 1, 2022
2.36 B VND
Jan 1, 2023
-3.23 B VND
Jan 1, 2024
4.23 B VND
The Enlie Pharmaceutical JSC EBITDA history
YEAREBITDAYoY
4.23 BVND-231.10%
-3.23 BVND-236.91%
2.36 BVND-156.32%
-4.19 BVND-64.32%
-11.74 BVND+290.39%
-3.01 BVND-120.53%
14.65 BVND+66.34%
8.80 BVND+30.86%
6.73 BVND+33.25%
5.05 BVND-54.11%
11.00 BVND—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Enlie Pharmaceutical JSC Stock analysis

What does Enlie Pharmaceutical JSC do? Enlie Pharmaceutical JSC generates revenue primarily through the manufacture and commerce of pharmaceutical preparations, medical equipment, and health supplements. The company leverages its core expertise in these healthcare categories to serve the market, establishing its primary income streams around the production and sale of these essential health products. In addition to its pharmaceutical operations, the firm has diversified its business model by expanding into the real estate industry. This segment involves the development of various commercial and residential infrastructures which are then made available for lease, providing an additional layer of financial activity beyond its core healthcare focus. Enlie Pharmaceutical JSC is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enlie Pharmaceutical JSC stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enlie Pharmaceutical JSC is 4.23 B VND in 2024.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Enlie Pharmaceutical JSC changed from -3.23 B VND to 4.23 B VND, representing a -231.10% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Enlie Pharmaceutical JSC since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s VND is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Enlie Pharmaceutical JSC historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Enlie Pharmaceutical JSC

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Enlie Pharmaceutical JSC